KK
CPRX

KLP Kapitalforvaltning’s Catalyst Pharmaceutical CPRX Stock Holding History

KLP Kapitalforvaltning’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-73,500
Closed -$1.82M – 2158
2026
Q1 		$1.82M Buy
73,500
+900
+1% +$21.4K 0.01% 751
2025
Q4 		$1.69M Buy
72,600
+33,500
+86% +$746K 0.01% 781
2025
Q3 		$770K Hold
39,100
– – ﹤0.01% 1176
2025
Q2 		$848K Buy
39,100
+2,100
+6% +$49.6K ﹤0.01% 1070
2025
Q1 		$897K Hold
37,000
– – ﹤0.01% 986
2024
Q4 		$772K Buy
+37,000
New +$795K ﹤0.01% 1110

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KLP Kapitalforvaltning's CPRX Position: Q2 2026 in Review

KLP Kapitalforvaltning sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 73,500 shares — an estimated $1.82M sold.

KLP Kapitalforvaltning first reported a position in CPRX in Q4 2024 and held it in 6 quarters. The position peaked at $1.82M in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • KLP Kapitalforvaltning reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • KLP Kapitalforvaltning sold 73,500 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.82M.
  • KLP Kapitalforvaltning first reported a position in Catalyst Pharmaceutical in Q4 2024 and held it in 6 quarters.
  • KLP Kapitalforvaltning's Catalyst Pharmaceutical position peaked at $1.82M in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.